Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1904)	11/13/2002 10:49:06 AM
From: Jibacoa	Read Replies (1) of 2344

EDMONTON, Nov. 13 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) announced today that the Company has completed enrolment of the planned 166 patients in its Phase IIb clinical trial with BLP25 Liposomal vaccine. There are now 168 patients enrolled into the trial. The controlled, randomized study involves patients with advanced non-small cell lung cancer (NSCLC) and enrolment was conducted at 13 sites in Canada and four in the United Kingdom. The trial began in August 2000. Final recruitment in the trial has been extended to allow a few previously identified patients the opportunity to be included in the trial. Enrolment for these identified patients is expected to close later this month.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next